IL6R and rheumatoid arthritis: Most important differences between the T-cell composition of RA patients on effective IL-6R blocker therapy and early, active, untreated RA patients are the strikingly low number of CD8+ cells and the higher prevalence of Th17 and Treg cells in the IL-6R blocker-treated patients.